NCT00258817View on ClinicalTrials.gov

Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

August 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Virus Vaccine (Fluzone®)

0.25 mL, Intramuscular (Day 0 and Day 28)

BIOLOGICAL

Influenza Virus Vaccine (Fluzone®)

0.25 mL, Intramuscular (Day 0)

Trial Locations (1)

23510

Norfolk

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00258817 - Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine | Biotech Hunter | Biotech Hunter